| abstract |
The present invention relates generally to therapeutics targeting the bacterium, Porphyromonas gingivalis, including its protease, lysine Porphyromonas gingivalis protease (Kgp), and its treatment of conditions associated with Porphyromonas gingivalis infection , including brain disorders such as Alzheimer's disease. In certain embodiments, the present invention provides compounds of Formula I as described herein, and pharmaceutically acceptable salts thereof. |